Simulations Plus Partners with Big Pharma to Accelerate AI-Driven QSP Modeling

  • Simulations Plus has secured a funded partnership with an unnamed global pharmaceutical company to deploy its AI-enabled QSP modeling engine, Turin, in active therapeutic development programs.
  • The collaboration aims to reduce QSP model development time by leveraging AI for mechanistic model structure exploration.
  • Turin's capabilities are enhanced by a technical collaboration with NVIDIA, announced in May 2026.
  • The partnership will initially focus on one therapeutic program, with plans to expand into additional programs.

This partnership represents a strategic validation of AI's role in streamlining complex biological modeling processes. As pharmaceutical companies face increasing pressure to accelerate drug development timelines, solutions like Turin that combine computational power with scientific expertise could become critical differentiators. The collaboration with NVIDIA suggests this is part of a broader industry trend toward leveraging high-performance computing infrastructure for biopharmaceutical R&D.

Adoption Pace
How quickly the pharmaceutical partner will expand Turin's use across additional therapeutic programs.
Technical Validation
Whether Turin can demonstrate measurable time savings and model accuracy improvements in real-world drug development settings.
Competitive Positioning
The extent to which this partnership differentiates Simulations Plus in the AI-accelerated drug development space.